AR101393A1 - COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 - Google Patents

COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2

Info

Publication number
AR101393A1
AR101393A1 ARP150102462A ARP150102462A AR101393A1 AR 101393 A1 AR101393 A1 AR 101393A1 AR P150102462 A ARP150102462 A AR P150102462A AR P150102462 A ARP150102462 A AR P150102462A AR 101393 A1 AR101393 A1 AR 101393A1
Authority
AR
Argentina
Prior art keywords
alkyl
monohalo
polyhalo
compounds
4oxy
Prior art date
Application number
ARP150102462A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR101393A1 publication Critical patent/AR101393A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP150102462A 2014-08-01 2015-07-31 COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 AR101393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14179599 2014-08-01

Publications (1)

Publication Number Publication Date
AR101393A1 true AR101393A1 (es) 2016-12-14

Family

ID=51257438

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102462A AR101393A1 (es) 2014-08-01 2015-07-31 COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2

Country Status (15)

Country Link
US (1) US10112949B2 (enExample)
EP (1) EP3174880B1 (enExample)
JP (1) JP6615864B2 (enExample)
KR (1) KR102531693B1 (enExample)
CN (1) CN106573935B (enExample)
AR (1) AR101393A1 (enExample)
AU (1) AU2015295299B2 (enExample)
BR (1) BR112017001998A2 (enExample)
CA (1) CA2954218C (enExample)
EA (1) EA031038B1 (enExample)
ES (1) ES2702192T3 (enExample)
JO (1) JO3601B1 (enExample)
MX (1) MX2017001453A (enExample)
TW (1) TWI696625B (enExample)
WO (1) WO2016016381A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
EP3227295B1 (en) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
PL3389727T3 (pl) * 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET
CA3003962A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
ES2991283T3 (es) 2017-11-24 2024-12-03 Sumitomo Pharma Co Ltd Derivado de 6,7-dihidropirazolo[1,5-a]pirazinona y aplicación médica del mismo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU2006226669B2 (en) * 2005-03-23 2011-12-08 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EP2651222A4 (en) 2010-12-17 2014-04-30 Univ Vanderbilt BICYCLIC TRIAZOL AND PYRAZOLLACTAME AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
RU2610262C2 (ru) 2011-11-03 2017-02-08 Мерк Шарп И Доум Корп. ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013192350A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192347A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CN104736156A (zh) * 2012-06-20 2015-06-24 范德比尔特大学 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物
KR20150070187A (ko) * 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
RU2708391C2 (ru) * 2014-08-01 2019-12-06 Янссен Фармацевтика Нв 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2

Also Published As

Publication number Publication date
CA2954218C (en) 2022-11-29
ES2702192T3 (es) 2019-02-27
BR112017001998A2 (pt) 2017-12-12
JO3601B1 (ar) 2020-07-05
CN106573935A (zh) 2017-04-19
EA201692496A1 (ru) 2017-06-30
AU2015295299A1 (en) 2017-01-19
TW201609742A (zh) 2016-03-16
JP6615864B2 (ja) 2019-12-04
WO2016016381A1 (en) 2016-02-04
KR102531693B1 (ko) 2023-05-10
US20180222908A1 (en) 2018-08-09
CN106573935B (zh) 2020-01-17
EP3174880A1 (en) 2017-06-07
US10112949B2 (en) 2018-10-30
CA2954218A1 (en) 2016-02-04
KR20170032464A (ko) 2017-03-22
MX2017001453A (es) 2017-05-11
EP3174880B1 (en) 2018-09-26
AU2015295299B2 (en) 2019-05-02
EA031038B1 (ru) 2018-11-30
TWI696625B (zh) 2020-06-21
JP2017523201A (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
AR101393A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR132512A2 (es) Compuesto de aminoalquilbenzotiazepina, composición farmacéutica que lo comprende y método para tratar el estreñimiento en un sujeto que lo necesita
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
AR101392A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
MX378315B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
BR112017000943A2 (pt) ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
EA201592252A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MX2017001554A (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR112264A1 (es) Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR075368A1 (es) Inhibidores de glicosilceramida sintasa
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR091520A1 (es) Inhibidores piranopiridona de tanquirasa
AR091731A1 (es) Antagonistas del receptor de mineralocorticoides

Legal Events

Date Code Title Description
FB Suspension of granting procedure